U.S. Code · Título 21
FDA rare neurodegenerative disease grant program
21 U.S.C. § 360ee–1
Office of the Law Revision Counsel · release 119-142
Se muestra el texto operativo de la sección. Las notas estatutarias y el historial de enmiendas están en la fuente oficial.
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—
to increase efficiency and productivity of clinical development of therapies, including through—
(Pub. L. 117–79, § 5, Dec. 23, 2021, 135 Stat. 1537.)